

**From:** [Jarvis, Candace](#)  
**To:** [James L'Italien, PhD \(jlitalien@avexis.com\)](#)  
**Cc:** [Nancy Boman](#); [Byrnes, Andrew](#); [Jarvis, Candace](#)  
**Subject:** BLA 125694/0| AveXis, Inc| Information Request 52 (PLEASE RESPOND BY APRIL 19, 2019)  
**Date:** Monday, April 15, 2019 10:37:16 AM **Attachments:**  
[image013.png](#)

---

Good morning Dr. L'Italien,

We have the following request for information regarding BLA 125694/0. Please respond by April 19, 2019.

For all DP lots manufactured by AveXis that have been tested to date in the (b) (4) total protein assay, please provide the lot number and total protein result.  
Please acknowledge receipt

*Regards,*

*Candace N. Jarvis*  
*Regulatory Project Manager*  
*Center for Biologics Evaluation and Research*  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8315  
[candace.jarvis@fda.hhs.gov](mailto:candace.jarvis@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.